Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000229 · ClinicalTrials.gov registry record · Phase 2
Buprenorphine Detox With Two Types of Treatment. BBD II - 11
A Phase 2 study of Opioid-Related Disorders, sponsored by University of Vermont.
- Completed
- Registry status
- Phase 2
- Development phase
- 1
- Study location
NCT00000229 is a Phase 2 study of Opioid-Related Disorders that has completed, run by University of Vermont. The trial reports 1 study location across 1 state.
The verdict
NCT00000229, a Phase 2 study of Opioid-Related Disorders, has completed, sponsored by University of Vermont.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1
- Study location
Study Summary
The purpose of this study is to compare overall treatment outcome between behavioral versus enhanced behavioral treatment types.
Conditions Studied
Interventions
- DRUG Buprenorphine
Study Locations (1)
Vermont
- Treatment Research Center - Burlington
Trial Details
| Field | Value |
|---|---|
| Start Date | 1995-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000229
The ClinicalTrials.gov registry entry for NCT00000229 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is University of Vermont, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Opioid-Related Disorders appearing as the primary indexed condition, and to 1 intervention - of which Buprenorphine is the first listed.
NCT00000229 reports 1 study location spanning 1 distinct geographic area - top geographies include Vermont.
Frequently Asked Questions
What is clinical trial NCT00000229 about?
NCT00000229 is a clinical study titled "Buprenorphine Detox With Two Types of Treatment. BBD II - 11". The purpose of this study is to compare overall treatment outcome between behavioral versus enhanced behavioral treatment types.
What is the current status of trial NCT00000229?
This trial is currently completed. It is a Phase 2 study. The study started on 1995-10.
What conditions does trial NCT00000229 study?
This clinical trial studies the following conditions: Opioid-Related Disorders.
What interventions are being tested in trial NCT00000229?
The interventions under investigation include: Buprenorphine (DRUG).
Who is sponsoring clinical trial NCT00000229?
This trial is sponsored by University of Vermont, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00000229 being conducted?
This trial has 1 study location across Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid-Related Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Psilocybin in Cancer Pain Study
RECRUITING · Phase 2
-
Neurocognitive Mechanisms Underlying Smartphone-Assisted Prevention of Relapse in Opioid Use Disorder
RECRUITING · Phase 2
-
Alternate-Day Buprenorphine Administration. Phase VII - 8
COMPLETED · Phase 2
-
Alternate Day Buprenorphine Administration, Phase IX - 14
COMPLETED · Phase 2
-
Methylnaltrexone for Opioid-induced Constipation in Cancer Patients
COMPLETED · Phase 2
-
Treatment of Opioid/Heroin Dependence: Comparison of Three Medication Dosing Regimens
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.